Hot off the press! 📢 Our Q3 2026 Gene, Cell and RNA Therapy Landscape Report, developed with Citeline, is here.
Explore seven new approvals, an expanding clinical pipeline and the latest advancements shaping the field.
Read more: https://t.co/kUwiaoqENv
#ASGCT#CGT
“Right to Try 2.0” gets the problem right and the solution wrong. N-of-1 gene editing needs faster, smarter regulation, not an end run around #FDA. When the treatment may be the first human exposure to a bespoke genetic medicine, oversight is a safeguard, not red tape. h/t @HollyLynchez@SteveJoffe@AhrensNicklas@kiranmusunuru #GeneTherapy #GeneEditing https://t.co/Jz9F3QFEPv
Science can't thrive on chaos & uncertainty. Delayed reviews, unpredictable funding decisions and fewer grants slows and prevents discoveries and development of new therapies that patients are waiting for. Predictable, sustained support for biomedical research is not optional. It is what turns science into medicines. @statnews #Science #Research #cancerresearch https://t.co/WL8G6khFdu
We invite you to join the Association of Academic Physiatrists (AAP) and the AAP Regenerative Rehabilitation Consortium (ARRC) for Regen Rehab '26, October 22-24, 2026, in Rochester, Minnesota.
#mayoclinicpmr@AAPhysiatrists#regenmed#physicalmedicine
The AAP Fall Summit brings together world-class leaders in #rehab and #regenerativemedicine.
We're thrilled to welcome Dr. Diana Farmer, renowned fetal surgeon & Chair of Surgery at @UCDavisHealth as keynote speaker for PRAM & Regen Rehab '26.
👉https://t.co/f3I3FW5eg2
Join us in Rochester this fall for a unique opportunity to engage with leading experts and help shape the future of regenerative rehabilitation medicine. #physiatry https://t.co/jaliFMROtv #mayoclinic
We look forward to hearing about this historic discovery, the research advances it has made possible, & where the science is headed next. Join us in Kyoto this October for the ISSCR iPSC 20th Anniversary Symposium as we celebrate this scientific milestone.
https://t.co/Zr4doQICk4
In a child with advanced nephroblastoma, T-cell therapy targeting preferentially expressed antigen in melanoma led to a 69% tumor reduction, with molecular, metabolic, and histologic evidence of complete remission at 200 days. Full case details: https://t.co/Q87Q8z6RSA
🚨Urgent need for physician education in cell and gene therapy. >45 cell and gene therapies approved in this new pillar of medicine requires medical education to adapt to train clinicians on these complex products. 👏@ShanStraderDO & colleagues 🧵👇
Cellular Therapy Fellowship✅
I am forever grateful for my training experience and opportunity to learn from the brightest minds. I am very thankful to start my career at the best hospital,@MayoClinic !